What is Attruby for? A comprehensive guide to its use in ATTR-CM
•
2 min read
In November 2024, the U.S. Food and Drug Administration (FDA) approved Attruby (acoramidis) to treat adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This oral medication serves a crucial role in reducing death and hospitalizations related to heart problems caused by this rare and serious condition. If you're asking, **'What is Attruby for?'**, this guide will explain its purpose, function, and other important information for patients.
